Disclosures: Madhumita Premkumar: Nothing to Disclose, Kamal Kajal: Nothing to Disclose, Manhal Izzy: Mallinckrodt: Speaking and Teaching, Bhupendra Sihag: Nothing to Disclose, Ajay Bahl: Nothing to Disclose, Vishesh Kumar: Nothing to Disclose, Ajay Duseja: Nothing to Disclose, Akash Roy: Nothing to Disclose, Sahaj Rathi: Nothing to Disclose, Harish Bhujade: Nothing to Disclose, Rohit Mehtani: Nothing to Disclose, Nipun Verma: Nothing to Disclose, SUNIL TANEJA: Nothing to Disclose, Jasvinder Nain: Nothing to Disclose 2621 PREDICTORS OF TREATMENT FAILURE AND RESISTANCE ASSOCIATED SUBSTITUTIONS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTIONS - HCV ELIMINATION EXPERIENCE FROM THE PUNJAB MODEL IN INDIA Radha Dhiman 1 Madhumita Premkumar 2 Jasvinder Nain 2 Ajay Duseja 2 EkTA Gupta 3 Sahaj Rathi 2 SUNIL TANEJA 2 Surender Singh 1 Akash Roy 1 Anchal Sandhu 2 Prerna Sharma 2 Gagandeep Singh Grover 4 , 1 SGPGIMS, Lucknow, India, 2 PGIMER, Chandigarh, India, 3 ILBS, New Delhi, India, 4 Punjab Governmaent, Punjab Background: The prevalence of HCV is 3.6% in the state of in Punjab, India with an estimated 728,000 viremic chronic hepatitis C (CHC) patients and HCV cure rate the national hepatitis C elimination programme (NVHCP) is 91.6% (Dhiman RK et al, J Hepatol 71(6):1076-1085)
With walk-ins welcome and treatments starting from just $99, plus the ability to use your FSA/HSA, achieving your health goals has never been more accessible
Your support and feedback help us continue to grow and provide the best care possible
From the concentration, the injection volume is calculated: Volume (ml) = desired dose (mg) Concentration (mg/ml)
It is often better to maintain a consistent, moderate dose that your body can actually process and utilize efficiently
